CD3E and neoplasm: In the present study we demonstrate that the amino-terminus of CD3ε can be modified with a mesothelin-specific scFv and that the engineered CD3ε is combined with other TCR subunits to form a functional TCR complex with novel target specificity resulting in T cell activation, cytokine release and anti-tumor activity.